...
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Society of Biomaterials Graduate Degree Candidate Student Research Award. Matrix metalloproteinase inhibitor within an absorbable coating for vascular applications: delivery device characterization and reduction of smooth muscle cell proliferation an
【24h】

Society of Biomaterials Graduate Degree Candidate Student Research Award. Matrix metalloproteinase inhibitor within an absorbable coating for vascular applications: delivery device characterization and reduction of smooth muscle cell proliferation an

机译:生物材料学会研究生学位候选学生研究奖。可吸收涂层中的基质金属蛋白酶抑制剂,用于血管应用:输送装置的表征和平滑肌细胞增殖的减少

获取原文
获取原文并翻译 | 示例
           

摘要

Significant occurrences of arterial restenosis remain a complicating factor of endovascular stent implantation. The incorporation of GM6001, a matrix metalloproteinase inhibitor (MMPI), into a poly(lactide-co-glycolide) (PLGA) absorbable coating for 316L stainless steel is proposed as a means to reduce the rate of smooth muscle cell proliferation and migration. Coatings were fabricated using a solvent evaporation technique, and the surfaces were characterized by noncontacting profilometry and scanning electron microscopy. Sufficient degradation of the PLGA determined by gel permeation chromatography occurred to release adequate amounts of the GM6001 from the coating within a 7-day period. A cumulative GM6001 release at day 42 was determined to be 77.8 +/- 1.4% of the actual GM6001 content within the coating. The coating containing the GM6001 reduced the rate of in vitro cell growth of human aortic smooth muscle cell (HASMC) by 30.7 and 37.4% compared to the metallic substrate only after 4 and 7 days, respectively. However, the MMP-2 activity normalized to cell number was not statistically different between the GM6001 releasing coating and the metal substrate. Using a scrape wound injury assay, the migration of HASMCs was shown to be decreased by 21.4% with GM6001 released from the PLGA coating compared to metallic substrate only. These results suggest that releasing a MMPI from an absorbable coating of a metallic substrate provides a reduction of HASMC proliferation and migration rates, while preserving the overall MMP activity in efforts to retain normal cellular regulation.
机译:动脉再狭窄的重要发生仍然是血管内支架植入的复杂因素。提出将GM6001(一种基质金属蛋白酶抑制剂(MMPI))掺入316L不锈钢的聚(丙交酯-共-乙交酯)(PLGA)可吸收涂层中,以降低平滑肌细胞增殖和迁移的速率。使用溶剂蒸发技术制备涂层,并通过非接触轮廓仪和扫描电子显微镜对表面进行表征。发生了由凝胶渗透色谱法确定的PLGA的充分降解,从而在7天的时间内从涂层中释放出适量的GM6001。测定第42天的累积GM6001释放为包衣中实际GM6001含量的77.8 +/- 1.4%。仅在第4天和第7天后,与金属基质相比,含有GM6001的涂层就使人主动脉平滑肌细胞(HASMC)的体外细胞生长速率分别降低了30.7%和37.4%。但是,归一化为细胞数的MMP-2活性在释放GM6001的涂层和金属基材之间没有统计学差异。使用刮擦伤试验,从PLGA涂层释放的GM6001与仅金属基材相比,表明HASMCs的迁移减少了21.4%。这些结果表明,从金属基质的可吸收涂层中释放MMPI可降低HASMC的增殖和迁移速率,同时保留总体MMP活性以保持正常的细胞调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号